 <h1>Vedolizumab Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><h2>In Summary</h2><p><b>Commonly reported side effects of vedolizumab include:</b> nasopharyngitis. <b>Other side effects include:</b> upper respiratory tract infection and fatigue.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to vedolizumab: intravenous powder for solution</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, vedolizumab may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking vedolizumab:</p><p>
<i>More common</i>
</p><ul>
<li>Body aches or pain</li>
<li>chills</li>
<li>difficulty with breathing</li>
<li>ear congestion</li>
<li>fever</li>
<li>headache</li>
<li>loss of voice</li>
<li>nasal congestion</li>
<li>runny nose</li>
<li>sneezing</li>
<li>sore throat</li>
<li>unusual tiredness or weakness</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Back pain</li>
<li>chest tightness</li>
<li>flushing</li>
<li>nausea and vomiting</li>
<li>weakness</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Cough</li>
<li>difficulty with swallowing</li>
<li>dizziness</li>
<li>fast heartbeat</li>
<li>hives, itching, or skin rash</li>
<li>puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue</li>
<li>tightness in the chest</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Abdominal or stomach pain</li>
<li>blurred vision</li>
<li>clay-colored stools</li>
<li>confusion</li>
<li>convulsions</li>
<li>dark urine</li>
<li>drowsiness</li>
<li>headache</li>
<li>loss of appetite</li>
<li>lower back or side pain</li>
<li>painful or difficult urination</li>
<li>unpleasant breath odor</li>
<li>vomiting of blood</li>
<li>yellow eyes or skin</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of vedolizumab may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Difficulty with moving</li>
<li>muscle pain or stiffness</li>
<li>pain in the joints</li>
</ul><p>
<!-- end intravenous powder for solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to vedolizumab: intravenous powder for injection</i></p><h3>General</h3><p>The most common adverse reactions were nasopharyngitis, headache, arthralgia, nausea, pyrexia, upper respiratory tract infection, fatigue, cough, bronchitis, influenza, back pain, rash, pruritus, sinusitis, oropharyngeal pain, and pain in extremities.<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Rash, pruritus, eczema, erythema, night sweats, acne</p>
<p><b>Uncommon</b> (0.1% to 1%): Folliculitis<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Nausea, oropharyngeal pain, gastroenteritis, anal abscess, anal fissure, dyspepsia, constipation, abdominal distension, flatulence, hemorrhoids<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Frequency not reported</b>: Urinary tract infection<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Frequency not reported</b>: Elevations of transaminase, elevations of bilirubin, hepatitis, ALT elevations, AST elevations<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Infusion related reactions (e.g., infusion site reaction, infusion site pain, infusion site irritation)</p>
<p><b>Very rare</b> (less than 0.01%): Anaphylactic reaction (e.g., dyspnea, bronchospasm, urticaria, flushing, rash, increased blood pressure, increased heart rate)<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Influenza</p>
<p><b>Uncommon</b> (0.1% to 1%): Bacterial sepsis, septic shock</p>
<p><b>Frequency not reported</b>: Sepsis, tuberculosis, salmonella sepsis, Listeria meningitis, giardiasis, cytomegaloviral colitis<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Arthralgia (12%)</p>
<p><b>Common</b> (1% to 10%): Back pain, pain in extremities<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (12%) </p>
<p><b>Common</b> (1% to 10%): Paresthesia<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Rare</b> (less than 0.1%): Transitional cell carcinoma, carcinoid tumor of the appendix</p>
<p><b>Frequency not reported</b>: B-cell lymphoma, breast cancer, colon cancer, malignant hepatic neoplasm, malignant lung neoplasm, malignant melanoma, lung cancer of primary neuroendocrine carcinoma, renal cancer, squamous cell carcinoma<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Pyrexia, fatigue<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Nasopharyngitis (13%) </p>
<p><b>Common</b> (1% to 10%): Upper respiratory tract infection, cough, bronchitis, influenza, sinusitis </p>
<p><b>Very rare</b> (less than 0.01%): Pneumonia<sup>[Ref]</sup></p><h3>Local</h3><p><b>Uncommon</b> (0.1% to 1%): Infusion site reaction (e.g., infusion site pain, infusion site irritation), infusion related reaction, chills, feeling cold<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Hypertension<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Entyvio (vedolizumab)." Takeda Pharmaceuticals America, Lincolnshire, IL. </p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>Is Entyvio an immunosuppressant or a biologic?</li>
<li>How much does Entyvio cost per month?</li>
<li>Can I take antibiotics while on Entyvio?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about vedolizumab</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>114 Reviews</li>
<li>Drug class: selective immunosuppressants</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Vedolizumab Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Entyvio</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Crohn's Disease, Maintenance</li>
<li>Ulcerative Colitis</li>
<li>Crohn's Disease</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to vedolizumab: intravenous powder for injection</i></p><h3>General</h3><p>The most common adverse reactions were nasopharyngitis, headache, arthralgia, nausea, pyrexia, upper respiratory tract infection, fatigue, cough, bronchitis, influenza, back pain, rash, pruritus, sinusitis, oropharyngeal pain, and pain in extremities.<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Rash, pruritus, eczema, erythema, night sweats, acne</p><p><b>Uncommon</b> (0.1% to 1%): Folliculitis<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Nausea, oropharyngeal pain, gastroenteritis, anal abscess, anal fissure, dyspepsia, constipation, abdominal distension, flatulence, hemorrhoids<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Frequency not reported</b>: Urinary tract infection<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Frequency not reported</b>: Elevations of transaminase, elevations of bilirubin, hepatitis, ALT elevations, AST elevations<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Infusion related reactions (e.g., infusion site reaction, infusion site pain, infusion site irritation)</p><p><b>Very rare</b> (less than 0.01%): Anaphylactic reaction (e.g., dyspnea, bronchospasm, urticaria, flushing, rash, increased blood pressure, increased heart rate)<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Influenza</p><p><b>Uncommon</b> (0.1% to 1%): Bacterial sepsis, septic shock</p><p><b>Frequency not reported</b>: Sepsis, tuberculosis, salmonella sepsis, Listeria meningitis, giardiasis, cytomegaloviral colitis<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Arthralgia (12%)</p><p><b>Common</b> (1% to 10%): Back pain, pain in extremities<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (12%) </p><p><b>Common</b> (1% to 10%): Paresthesia<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Rare</b> (less than 0.1%): Transitional cell carcinoma, carcinoid tumor of the appendix</p><p><b>Frequency not reported</b>: B-cell lymphoma, breast cancer, colon cancer, malignant hepatic neoplasm, malignant lung neoplasm, malignant melanoma, lung cancer of primary neuroendocrine carcinoma, renal cancer, squamous cell carcinoma<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Pyrexia, fatigue<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Nasopharyngitis (13%) </p><p><b>Common</b> (1% to 10%): Upper respiratory tract infection, cough, bronchitis, influenza, sinusitis </p><p><b>Very rare</b> (less than 0.01%): Pneumonia<sup>[Ref]</sup></p><h3>Local</h3><p><b>Uncommon</b> (0.1% to 1%): Infusion site reaction (e.g., infusion site pain, infusion site irritation), infusion related reaction, chills, feeling cold<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Hypertension<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Entyvio (vedolizumab)." Takeda Pharmaceuticals America, Lincolnshire, IL. </p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>Is Entyvio an immunosuppressant or a biologic?</li>
<li>How much does Entyvio cost per month?</li>
<li>Can I take antibiotics while on Entyvio?</li>
</ul><h2>More about vedolizumab</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>114 Reviews</li>
<li>Drug class: selective immunosuppressants</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Vedolizumab Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Crohn's Disease, Maintenance</li>
<li>Ulcerative Colitis</li>
<li>Crohn's Disease</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>